Granules India Limited achieved a landmark performance in FY 2026, crossing INR 50,000 million in revenue with 20% year-on-year growth. The company marked six consecutive quarters of sequential growth, driven by a strategic shift towards complex generics and the expansion of its peptide CDMO segment. Despite external cost pressures, the organization strengthened its foundations, enhanced its global generic ranking, and maintained a disciplined approach to capital allocation and operational efficiency.
Financial Highlights of FY 2026
Granules India delivered a landmark financial performance for FY 2026, with total revenue reaching INR 53,656 million. The company’s focus on high-value formulations and a strategic shift towards complex generics contributed to a robust gross margin of 65%, an improvement of 355 basis points year-on-year. Furthermore, EBITDA for the year stood at INR 11,851 million, up 25% compared to the previous year, with margins expanding to 22.1%.
Strategic Growth Pillars
The company’s growth is underpinned by several key strategic initiatives. The peptide CDMO business emerged as a significant new revenue vertical following the acquisition of Senn Chemicals AG, contributing INR 1,593 million to the annual revenue and achieving positive EBITDA by the fourth quarter. Additionally, the company has improved its global standing, reaching the 27th position among U.S. generic companies by sales value, up from 74th in FY 2021.
Operational Stability and Future Outlook
Granules India has prioritized operational resilience and regulatory readiness. The Gagillapur facility has seen significant progress in remediation and quality systems, while the company continues to invest in digital infrastructure and R&D. For the upcoming year, the firm plans to focus on scaling commercial contributions, expanding its complex generics pipeline, and maintaining a disciplined capital expenditure strategy, with approximately INR 600-odd crores earmarked for broad-based projects, including a new distribution center in the U.S.
Focus on Innovation and Sustainability
Commitment to responsible growth remains a core focus, evidenced by EcoVadis Gold rating and Platinum Plus zero waste to landfill certification at the Gagillapur site. R&D efforts remain aligned with portfolio depth, with the company filing 6 U.S. ANDAs and 6 U.S. DMFs during the year, reinforcing its focus on high-barrier, complex products. As the company moves into the next phase of growth, it remains well-positioned to deliver sustainable, value-led results.
Source: BSE
